NR2B Selective NMDA Antagonists: The Evolution of the Ifenprodil-Type Pharmacophore

Borza, István; Domány, György

doi:10.2174/156802606776894456

Cited by 85 publications

(58 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The broad SAR governing these compound classes has typically involved two aromatic rings separated by a carbon linker that often contains nitrogen (Chenard and Menniti, 1999;Tamiz et al, 1999;Nikam and Meltzer, 2002;Borza and Domá ny, 2006;Layton et al, 2006). A variety of chemically distinct linkers and substituted aryl compounds retain activity, leading to considerable diversity in ligand structure.…”

Section: The Glun2b Amino-terminal Domain Harbors a Binding Site For mentioning

confidence: 99%

Control of Assembly and Function of Glutamate Receptors by the Amino-Terminal Domain

Hansen¹,

Furukawa²,

Traynelis³

2010

Mol Pharmacol

103

View full text Add to dashboard Cite

The extracellular amino-terminal domains (ATDs) of the ionotropic glutamate receptor subunits form a semiautonomous component of all glutamate receptors that resides distal to the membrane and controls a surprisingly diverse set of receptor functions. These functions include subunit assembly, receptor trafficking, channel gating, agonist potency, and allosteric modulation. The many divergent features of the different ionotropic glutamate receptor classes and different subunits within a class may stem from differential regulation by the amino-terminal domains. The emerging knowledge of the structure and function of the amino-terminal domains reviewed here may enable targeting of this region for the therapeutic modulation of glutamatergic signaling. Toward this end, NMDA receptor antagonists that interact with the GluN2B ATD show promise in animal models of ischemia, neuropathic pain, and Parkinson's disease.

show abstract

Section: The Glun2b Amino-terminal Domain Harbors a Binding Site For mentioning

confidence: 99%

Control of Assembly and Function of Glutamate Receptors by the Amino-Terminal Domain

Hansen¹,

Furukawa²,

Traynelis³

2010

Mol Pharmacol

103

View full text Add to dashboard Cite

show abstract

“…This heterogeneity among NMDA receptor subunits creates an opportunity to identify subunit selective agonists, partial agonists, antagonists, and modulators. Among these, most success has been achieved with the development of NR2B selective antagonists, which have received significant attention as potential therapeutic candidates (Chazot, 2004;Borza and Domany, 2006;Layton et al, 2006).…”

Section: Nr2d-containing Receptors (46-fold) Analysis Of Chimericmentioning

confidence: 99%

Subunit-Specific Agonist Activity at NR2A-, NR2B-, NR2C-, and NR2D-ContainingN-Methyl-d-aspartate Glutamate Receptors

et al. 2007

View full text Add to dashboard Cite

The four N-methyl-D-aspartate (NMDA) receptor NR2 subunits (NR2A-D) have different developmental, anatomical, and functional profiles that allow them to serve different roles in normal and neuropathological situations. Identification of subunit-selective NMDA receptor agonists, antagonists, or modulators could prove to be both valuable pharmacological tools as well as potential new therapeutic agents. We evaluated the potency and efficacy of a wide range of glutamate-like compounds at NR1/NR2A, NR1/NR2B, NR1/NR2C, and NR1/NR2D receptors. Twenty-five of 53 compounds examined exhibited agonist activity at the glutamate binding site of NMDA receptors. Concentration-response relationships were determined for these agonists at each NR2 subunit. We find consistently higher potency at the NR2D subunit for a wide range of dissimilar structures, with (2S,4R)-4-methylglutamate (SYM2081) showing the greatest differential potency between NR2A-and NR2D-containing receptors (46-fold). Analysis of chimeric NR2A/D receptors suggests that enhanced agonist potency for NR2D is controlled by residues in both of the domains (Domain1 and Domain2) that compose the bilobed agonist binding domain. Molecular dynamics (MD) simulations comparing a crystallography-based hydrated NR1/NR2A model with a homology-based NR1/NR2D hydrated model of the agonist binding domains suggest that glutamate exhibits a different binding mode in NR2D compared with NR2A that accommodates a 4-methyl substitution in SYM2081. Mutagenesis of functionally divergent residues supports the conclusions drawn based on the modeling studies. Despite high homology and conserved atomic contact residues within the agonist binding pocket of NR2A and NR2D, glutamate adopts a different binding orientation that could be exploited for the development of subunit selective agonists and competitive antagonists.NMDA receptors are ligand-gated ion channels that mediate a component of excitatory synaptic transmission that can trigger changes in synaptic strength (Malenka and Nicoll, 1993). NMDA receptors have also been implicated in the pathophysiology of stroke and brain injury (Wang and Shuaib, 2005), epilepsy (Mares et al., 2004), as well as a range of psychiatric disorders (Heresco-Levy and Javitt, 1998;MacDonald and Chafee, 2006). NMDA receptors are tetrameric protein complexes composed of a combination of glycine-binding NR1 subunits and glutamate-binding NR2 subunits (Dingledine et al., 1999;Chen and Wyllie, 2006).

show abstract

“…[6,7] NR2B subtype-selective antagonists are a family of compounds that have aroused research interest, and the ifenprodil prototype (1) served as a template to design a large number of much more selective analogues such as Ro 25-6981 (2), CP 101,606 (3), CI-1041 (4), Ro 04-5595 (5), and benzimidazole derivative 6 (Figure 1), which have been shown to selectively bind at the so-called ifenprodil site. [8][9][10][11][12] These molecules showed neuroprotective effects in animal models without producing the undesirable side effects that are [ The ionotropic glutamate NMDA/NR2B receptor and its interaction with ifenprodil-like noncompetitive ligands were investigated by a combined ligand-based and target-based approach. First, we generated 3D pharmacophore hypotheses and identified common chemical features that are shared by a training set of well-known NR2B antagonists.…”

Section: Introductionmentioning

confidence: 99%

Computational Studies to Discover a New NR2B/NMDA Receptor Antagonist and Evaluation of Pharmacological Profile

et al. 2008

View full text Add to dashboard Cite

The ionotropic glutamate NMDA/NR2B receptor and its interaction with ifenprodil-like noncompetitive ligands were investigated by a combined ligand-based and target-based approach. First, we generated 3D pharmacophore hypotheses and identified common chemical features that are shared by a training set of well-known NR2B antagonists. The binding mode of the most representative ligand was also studied by molecular docking. Because the docking results and the suggested 3D pharmacophore model were in good agreement, we obtained new information about the NR2B ifenprodil site. The best pharmacophoric hypothesis was used as a query for in silico screening; this allowed the identification of new "hit". We synthesized "hit-compound" analogues, and some of the molecules showed significant activity both in binding and functional assay as well as in vivo anticonvulsant efficacy in DBA/2 mice. The most active derivatives also exhibited neuroprotective effects against glutamate-induced toxicity in HCN-1A cells.

show abstract

NR2B Selective NMDA Antagonists: The Evolution of the Ifenprodil-Type Pharmacophore

Cited by 85 publications

References 24 publications

Control of Assembly and Function of Glutamate Receptors by the Amino-Terminal Domain

Control of Assembly and Function of Glutamate Receptors by the Amino-Terminal Domain

Subunit-Specific Agonist Activity at NR2A-, NR2B-, NR2C-, and NR2D-ContainingN-Methyl-d-aspartate Glutamate Receptors

Computational Studies to Discover a New NR2B/NMDA Receptor Antagonist and Evaluation of Pharmacological Profile

Contact Info

Product

Resources

About